title: [SREBP-1 and fatty liver. Clinical relevance for diabetes, obesity, dyslipidemia and atherosclerosis].
abstract: Insulin resistance and visceral fat distribution usually play a major role in the development of clinical aspects of the metabolic syndrome, such as dyslipidemia, diabetes and atherosclerosis. In this review, the focus will be on some novel relationships with a fatty liver, for which susceptibility appears to be mediated by the activity of transcription factors, such as sterol regulatory element-binding protein 1 (SREBP-1). In addition to this molecular aspect therapeutic life-style modifications, such as weight reduction which are associated with increased insulin sensitivity and a decrease of fat in the liver will be discussed.
authors.affiliation: Herz-, Gefäß- und Diabeteszentrum u. Abteilung für Allgemeine Innere Medizin, Asklepios Klinik St. Georg, Asklepios Campus Hamburg, Medizinische Fakultät der Semmelweis-Universität, Lohmühlenstr. 5, 20099, Hamburg, Deutschland. d.mueller-wieland@asklepios.com
authors.forename: D
authors.initials: D
authors.lastname: Müller-Wieland
authors.forename: B
authors.initials: B
authors.lastname: Knebel
authors.forename: J
authors.initials: J
authors.lastname: Haas
authors.forename: J
authors.initials: J
authors.lastname: Kotzka
mesh_terms: D050197:Atherosclerosis / Q000378:metabolism*; D015415:Biomarkers / Q000097:blood; D003920:Diabetes Mellitus / Q000378:metabolism*; D005234:Fatty Liver / Q000378:metabolism*; D006801:Humans; D024821:Metabolic Syndrome / Q000378:metabolism*; D008954:Models, Biological; D009765:Obesity / Q000378:metabolism*; D051780:Sterol Regulatory Element Binding Protein 1 / Q000097:blood*
chemical_list: D015415:Biomarkers; C497387:SREBF1 protein, human; D051780:Sterol Regulatory Element Binding Protein 1